Charles River Laboratories Intl. Inc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $301.37 (market cap $14.23B), while iShares 7-10 Year Treasury Bond ETF trades at $89.39 (market cap $41.13B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 2.9× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and iShares 7-10 Year Treasury Bond ETF for 108 Days on average.
| CRL | IEF | |
|---|---|---|
Market Cap | $14.23B | $41.13B |
Volume | 1,176,885 | 10,340,382 |
Sector | Health | Fixed Income |
52-Week High | $310.77 | $97.99 |
52-Week Low | $149.93 | $88.92 |
Typical Hold Time | 33 Days | 108 Days |
Enterprise Value | $17.06B | — |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
IEF trades at $89.335, up 0.25% with a bearish technical signal from moving averages. The fund shows neutral oscillator readings with RSI at 52.94. Recent dividend payments of $0.31-$0.33 provide income, while bond market volatility and rising Treasury yields create headwinds. Support is clustered around $89 with resistance at $90.
The outlook remains cautious amid persistent bond market pressure. While dividend income offers stability, the bearish technical trend and macroeconomic uncertainty suggest limited near-term upside. Key risks include continued yield increases and inflation concerns that could pressure bond prices further.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →